Expert Interview
A Third View: Evaluating the impact of Merck’s first‑in‑class activin inhibitor Winrevair (sotatercept) on morbidity and mortality in PAH: insights from ZENITH and HYPERION trial data
Ticker(s): MRKInstitution: Santiam Hospital
- Pulmonologist at Santiam Hospital
- Treats 80-100 COPD patients monthly
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
